198 related articles for article (PubMed ID: 38087279)
1. BMC3PM: bioinformatics multidrug combination protocol for personalized precision medicine and its application in cancer treatment.
Mokhtari M; Khoshbakht S; Akbari ME; Moravveji SS
BMC Med Genomics; 2023 Dec; 16(1):328. PubMed ID: 38087279
[TBL] [Abstract][Full Text] [Related]
2. Network controllability-based algorithm to target personalized driver genes for discovering combinatorial drugs of individual patients.
Guo WF; Zhang SW; Feng YH; Liang J; Zeng T; Chen L
Nucleic Acids Res; 2021 Apr; 49(7):e37. PubMed ID: 33434272
[TBL] [Abstract][Full Text] [Related]
3. Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma.
Berlow NE; Rikhi R; Geltzeiler M; Abraham J; Svalina MN; Davis LE; Wise E; Mancini M; Noujaim J; Mansoor A; Quist MJ; Matlock KL; Goros MW; Hernandez BS; Doung YC; Thway K; Tsukahara T; Nishio J; Huang ET; Airhart S; Bult CJ; Gandour-Edwards R; Maki RG; Jones RL; Michalek JE; Milovancev M; Ghosh S; Pal R; Keller C
BMC Cancer; 2019 Jun; 19(1):593. PubMed ID: 31208434
[TBL] [Abstract][Full Text] [Related]
4. In silico drug combination discovery for personalized cancer therapy.
Jeon M; Kim S; Park S; Lee H; Kang J
BMC Syst Biol; 2018 Mar; 12(Suppl 2):16. PubMed ID: 29560824
[TBL] [Abstract][Full Text] [Related]
5. Precision medicine for suicidality: from universality to subtypes and personalization.
Niculescu AB; Le-Niculescu H; Levey DF; Phalen PL; Dainton HL; Roseberry K; Niculescu EM; Niezer JO; Williams A; Graham DL; Jones TJ; Venugopal V; Ballew A; Yard M; Gelbart T; Kurian SM; Shekhar A; Schork NJ; Sandusky GE; Salomon DR
Mol Psychiatry; 2017 Sep; 22(9):1250-1273. PubMed ID: 28809398
[TBL] [Abstract][Full Text] [Related]
6. An integrated computational strategy to predict personalized cancer drug combinations by reversing drug resistance signatures.
Wang X; Yang L; Yu C; Ling X; Guo C; Chen R; Li D; Liu Z
Comput Biol Med; 2023 Sep; 163():107230. PubMed ID: 37418899
[TBL] [Abstract][Full Text] [Related]
7. [Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].
Albin N; Mc Leer A; Sakhri L
Bull Cancer; 2018 Apr; 105(4):375-396. PubMed ID: 29501208
[TBL] [Abstract][Full Text] [Related]
8. Drug Repurposing for Cancer Therapy in the Era of Precision Medicine.
K W To K; Cho WCS
Curr Mol Pharmacol; 2022; 15(7):895-903. PubMed ID: 35156588
[TBL] [Abstract][Full Text] [Related]
9. PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data.
Piñeiro-Yáñez E; Reboiro-Jato M; Gómez-López G; Perales-Patón J; Troulé K; Rodríguez JM; Tejero H; Shimamura T; López-Casas PP; Carretero J; Valencia A; Hidalgo M; Glez-Peña D; Al-Shahrour F
Genome Med; 2018 May; 10(1):41. PubMed ID: 29848362
[TBL] [Abstract][Full Text] [Related]
10. Can Drug Repurposing Accelerate Precision Oncology?
Schipper LJ; Zeverijn LJ; Garnett MJ; Voest EE
Cancer Discov; 2022 Jul; 12(7):1634-1641. PubMed ID: 35642948
[TBL] [Abstract][Full Text] [Related]
11. MD-Miner: a network-based approach for personalized drug repositioning.
Wu H; Miller E; Wijegunawardana D; Regan K; Payne PRO; Li F
BMC Syst Biol; 2017 Oct; 11(Suppl 5):86. PubMed ID: 28984195
[TBL] [Abstract][Full Text] [Related]
12. Personalized tumor combination therapy optimization using the single-cell transcriptome.
Tang C; Fu S; Jin X; Li W; Xing F; Duan B; Cheng X; Chen X; Wang S; Zhu C; Li G; Chuai G; He Y; Wang P; Liu Q
Genome Med; 2023 Dec; 15(1):105. PubMed ID: 38041202
[TBL] [Abstract][Full Text] [Related]
13. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.
Cheng L; Schneider BP; Li L
J Am Med Inform Assoc; 2016 Jul; 23(4):741-9. PubMed ID: 27107440
[TBL] [Abstract][Full Text] [Related]
14. Personalized medicine and the clinical laboratory.
Pinho JR; Sitnik R; Mangueira CL
Einstein (Sao Paulo); 2014 Sep; 12(3):366-73. PubMed ID: 25295459
[TBL] [Abstract][Full Text] [Related]
15. Correction: BMC3PM: bioinformatics multidrug combination protocol for personalized precision medicine and its application in cancer treatment.
Mokhtari M; Khoshbakht S; Akbari ME; Moravveji SS
BMC Med Genomics; 2024 Jan; 17(1):13. PubMed ID: 38172948
[No Abstract] [Full Text] [Related]
16. Fangjiomics: revealing adaptive omics pharmacological mechanisms of the myriad combination therapies to achieve personalized medicine.
Duan DD; Wang Z; Zhang BL; Wang YY
Acta Pharmacol Sin; 2015 Jun; 36(6):651-3. PubMed ID: 26036241
[No Abstract] [Full Text] [Related]
17. Theranostic barcoded nanoparticles for personalized cancer medicine.
Yaari Z; da Silva D; Zinger A; Goldman E; Kajal A; Tshuva R; Barak E; Dahan N; Hershkovitz D; Goldfeder M; Roitman JS; Schroeder A
Nat Commun; 2016 Nov; 7():13325. PubMed ID: 27830705
[TBL] [Abstract][Full Text] [Related]
18. Optimization of personalized therapies for anticancer treatment.
Vazquez A
BMC Syst Biol; 2013 Apr; 7():31. PubMed ID: 23587292
[TBL] [Abstract][Full Text] [Related]
19. Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG study.
Kempowsky-Hamon T; Valle C; Lacroix-Triki M; Hedjazi L; Trouilh L; Lamarre S; Labourdette D; Roger L; Mhamdi L; Dalenc F; Filleron T; Favre G; François JM; Le Lann MV; Anton-Leberre V
BMC Med Genomics; 2015 Feb; 8():3. PubMed ID: 25888889
[TBL] [Abstract][Full Text] [Related]
20. Genomics and bioinformatics as pillars of precision medicine in oncology.
Canzoneri R; Lacunza E; Abba MC
Medicina (B Aires); 2019; 79(Spec 6/1):587-592. PubMed ID: 31864231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
